X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2025)
X4 Pharmaceuticals (XFOR) reported Gross Margin of 85.83% for Q4 2025, up 689.0% on a YoY basis from 10.88% in Q4 2024, and up 7.13% quarter-over-quarter from 80.11% in Q3 2025.
X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Gross Margin for 2 years, with the latest figure at 85.83% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 689.0% year-over-year to 85.83%; the trailing twelve-month figure through Dec 2025 stood at 83.6% (up 1477.0% YoY), and the FY2025 full-year result was 83.6%, up 1477.0% from the prior year.
- Gross Margin for Q4 2025 stood at 85.83%, up from 80.11% in the prior quarter.
- The five-year high for Gross Margin was 85.83% in Q4 2025, with the low at 52.4% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | 85.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 85.83% |
| Sep 30, 2025 | 80.11% |
| Jun 30, 2025 | 83.48% |
| Mar 31, 2025 | 83.63% |
| Dec 31, 2024 | 78.94% |
| Sep 30, 2024 | 59.46% |
| Jun 30, 2024 | 52.40% |